Blackstone Extends Reach Into Life Sciences And AI Data Infrastructure

robot
Abstract generation in progress

Blackstone (NYSE:BX) has expanded its investment focus into new sectors by committing up to US$400 million to Teva’s autoimmune drug program and arranging a US$2 billion financing package for QTS data centers to support AI capacity. These moves diversify Blackstone’s earnings beyond its traditional real estate, private equity, and credit strategies, aligning with long-term trends in healthcare and data usage. While these investments offer new growth drivers, investors should also consider the company’s valuation, high debt levels, and dividend coverage.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned